MicroRNA Down-regulate After Exposure to UV Radiation in Melanocytes of Women with a History of Melanoma
MicroRNAs in the melanocytes of women with a history of melanoma were down-regulated when exposed to ultraviolet radiation.
Researchers argue that immune therapies that target hormone-receptor-positive breast cancer is not the "dead end" it was once believed to be.
A phase 3 trial of patients with cutaneous melanoma found no difference in distant metastasis-free survival between those who underwent complete lymph node dissection and those who did not.
For Merkel-cell cancers—the deadliest and rarest type—there are no approved drugs once surgery and radiation fail.
Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.
Dr Jabbour discusses clinical decision making for chronic myeloid leukemia and the high price of newly approved drugs in an interview with Cancer Therapy Advisor.
From Oncology Nurse Advisor
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Multiple Myeloma May Be Linked to Pesticide Exposure
- Biomarker Identifies mCRC Patients Likely to Respond to Cetuximab
- Updated Outcomes From Multiple Myeloma Study Support New Standard of Care
- Stage IIIA NSCLC Quality Measures Associated With Improved Outcomes
- First-line Pembrolizumab Superior to Chemo for Patients With Advanced NSCLC
- Breast Cancer (Invasive) Treatment Regimens
- TRUS-biopsy Poorly Detects Prostate Cancer
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Cobimetinib Plus Atezolizumab Active in Colorectal Cancer
- Serum Carbonic Anhydrase IV Predictive of Bevacizumab Efficacy in Breast Cancer
- MicroRNA Down-regulate After Exposure to UV Radiation in Melanocytes of Women with a History of Melanoma
- Routine Prophylactic RT After Large-bore Thoracic Interventions Not Appropriate for Mesothelioma
- NDA Submission Initiated for Brigatinib in ALK+ Non-small Cell Lung Cancer
- Candesartan Unlikely to Mitigate Cardiac Events in Patients With Early Breast Cancer Undergoing Treatment
- Targeted Therapy Has Led to Better Survival Among African Americans, Caucasians